Opaleye reports 619,089 Karyopharm warrant shares

Karyopharm Therapeutics Inc. ownership update: Opaleye entities report beneficial ownership of 619,089 shares of common stock issuable upon exercise of warrants, immediately exercisable, representing 2.67% of the class as of March 31, 2026.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. ownership update: Opaleye entities report beneficial ownership of 619,089 shares of common stock issuable upon exercise of warrants, immediately exercisable, representing 2.67% of the class as of March 31, 2026. The percentage is calculated using 22,543,316 shares outstanding as of March 26, 2026 plus the shares issuable upon exercise. The statement is filed by Opaleye Management Inc., Opaleye, L.P., and James Silverman with respect to warrants directly held by the Fund.

Insights

Corporate Governance Analyst

Minority warrant position disclosed; control appears shared through adviser and fund.

The filing shows 619,089 shares issuable upon exercise of warrants that are immediately exercisable. Ownership is reported as 2.67% based on 22,543,316 shares outstanding as of March 26, 2026, and voting/dispositive power is reported as shared.

This is a routine ownership disclosure under Schedule 13G/A: subsequent filings will show any changes in holdings or control status.

Securities Compliance Advisor

Filing clarifies beneficial ownership and attribution among related reporting persons.

The statement attributes the warrants to the Fund, notes the Adviser’s role, and disclaims automatic beneficial‑owner status for Section 13 purposes. Signatures show Mr. Silverman signing in multiple capacities.

Regulatory consequence: this satisfies disclosure requirements; further material changes would require updated filings.

Key Figures

Warrant shares beneficially owned: 619,089 shares Percent of class: 2.67% Shares outstanding used in calculation: 22,543,316 shares

3 metrics

Warrant shares beneficially owned 619,089 shares issuable upon exercise of warrants, immediately exercisable (as of March 31, 2026)

Percent of class 2.67% based on 22,543,316 shares outstanding as of March 26, 2026 plus warrant shares

Shares outstanding used in calculation 22,543,316 shares shares outstanding as of March 26, 2026 reported by the issuer

Key Terms

warrants, beneficially owned, shared dispositive power, Schedule 13G/A

4 terms

warrants financial

"common stock issuable upon exercise of warrants that are immediately exercisable"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

beneficially owned regulatory

"the Fund beneficially owned 619,089 shares of common stock issuable upon exercise of warrants"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared Dispositive Power 619,089.00"

Schedule 13G/A regulatory

"This statement is filed by (i) Opaleye Management Inc. ..."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Opaleye report in KPTI?

Opaleye reports beneficial ownership of 619,089 shares issuable upon exercise of warrants, representing 2.67% of the class. The percentage is based on 22,543,316 shares outstanding as of March 26, 2026, plus the warrant shares.

Are the warrants exercisable now for KPTI?

Yes. The filing states the warrants are immediately exercisable. The Fund beneficially owned the 619,089 exercisable warrant shares as of March 31, 2026, per the disclosure.

Who filed the Schedule 13G/A for KPTI?

The statement was filed jointly by Opaleye Management Inc., Opaleye, L.P., and James Silverman, with the Adviser serving as investment adviser to the Fund and Mr. Silverman exercising control over the Adviser.

How was the 2.67% ownership percentage calculated?

The percentage uses 22,543,316 shares outstanding as of March 26, 2026, reported by the issuer, plus the shares issuable upon exercise of the warrants; the resulting ownership is 2.67%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 04:23 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Karyopharm Therapeutics Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

48576U205

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Opaleye Management Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 619,089.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 619,089.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

619,089.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.67 %

12

Type of Reporting Person (See Instructions)

IA, CO

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Opaleye, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 619,089.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 619,089.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

619,089.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.67 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

James Silverman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 619,089.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 619,089.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

619,089.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.67 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Karyopharm Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA, 02459
Item 2.
(a)	Name of person filing: This statement is filed by (i) Opaleye Management Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund") and (iii) James Silverman with respect to warrants directly held by the Fund. The Adviser serves as investment adviser to the Fund. Mr. Silverman exercises control over the Adviser. The filing of this statement should not be construed as an admission that any of the foregoing persons is, for the purposes of Section 13 of the Securities Exchange Act, the beneficial owner of the warrants reported herein.
(b)	Address or principal business office or, if none, residence: One Boston Place, 26th Floor, Boston, MA 02108
(c)	Citizenship: Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Delaware James Silverman - USA
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 48576U205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of March 31, 2026, the Fund beneficially owned 619,089 shares of common stock issuable upon exercise of warrants (the "Warrants") that are immediately exercisable. The percentage reported herein is based on 22,543,316 shares of common stock outstanding as of March 26, 2026, as reported by the Issuer in an 8-K filed with the Securities and Exchange Commission on March 27, 2026, plus the shares of common stock issuable upon exercise of the Warrants.
(b)	Percent of class: 2.67 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 619,089.00
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 619,089.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Opaleye Management Inc.

Signature:	/s/ James Silverman
Name/Title:	President
Date:	05/11/2026

Opaleye, L.P.

Signature:	/s/ James Silverman
Name/Title:	General Partner
Date:	05/11/2026

James Silverman

Signature:	/s/ James Silverman
Name/Title:	Individually
Date:	05/11/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement by and among the reporting persons